135 - Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age

Rapid Fire Presenter(s)

• 

  Christopher E. Harris, MD (he/him/his)

  Medical Director
  Enanta Pharmaceuticals
  Watertown, MA, United States

Co-Author(s)

• 

  John DeVincenzo, MD

  V.P. Translational Virology
  Enanta Pharmaceuticals
  Watertown, MA, United States
• SH

  Stephen Huang, M.D.

  Vice President
  Enanta Pharmaceuticals, Inc.
  Watertown, Massachusetts, United States
• SC

  Shijie Chen, PhD

  V.P. and Head of Biometrics
  Enanta Pharmaceuticals
  Watertown, Massachusetts, United States
• TN

  Taylor Ngo, MPH

  Enanta Pharmaceuticals
  Watertown, Massachusetts, United States
• AA

  Alaa Ahmad, PhD

  V.P. Clinical Pharmacology
  Enanta Pharmaceuticals
  Watertown, Massachusetts, United States
• SR

  Scott T Rottinghaus, MD

  Chief Medical Officer
  Enanta Pharmaceuticals
  Watertown, Massachusetts, United States